Foretinib was found to induce anti-cancer effects by the anti-phosphorylation of Met, which results in the induction of p53-dependent apoptosis; foretinib had more anti-cancer activity in endometrial cancer specimens with wild-type p53 than in specimens with p53 mutations. The gene discussed is TP53; the disease is endometrial cancer.